ITP - MDPI

13 downloads 0 Views 1MB Size Report
Feb 9, 2017 - Results from two randomized, placebo-controlled trials. ..... Vaan, G.; Reekers, P.; Vingerhoets, D.M.; Gabreels, F.J. Effect of thymectomy on myasthenia gravis and autoimmune thrombocytopenic purpura in a 13-year-old girl.
Journal of

Clinical Medicine Review

Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP) Anne Zufferey 1,2 , Rick Kapur 1,2,3 and John W. Semple 1,2,3,4,5, * 1 2 3 4 5

*

Keenan Research Centre for Biomedical Science, St. Michael’s Hospital, Toronto, ON M5B 1W8, Canada; [email protected] (A.Z.); [email protected] (R.K.) The Toronto Platelet Immunobiology Group, St. Michael’s Hospital, Toronto, ON M5B 1W8, Canada Canadian Blood Services, Toronto, ON M5B 1W8, Canada Department of Pharmacology, Medicine, and Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5B 1W8, Canada Division of Hematology and Transfusion Medicine, Lund University, 221 84 Lund, Sweden Correspondence: [email protected]; Tel.: +46-70-3012-2725

Academic Editor: Emmanuel Andrès Received: 28 December 2016; Accepted: 4 February 2017; Published: 9 February 2017

Abstract: Immune thrombocytopenia (ITP) is a complex autoimmune disease characterized by low platelet counts. The pathogenesis of ITP remains unclear although both antibody-mediated and/or T cell-mediated platelet destruction are key processes. In addition, impairment of T cells, cytokine imbalances, and the contribution of the bone marrow niche have now been recognized to be important. Treatment strategies are aimed at the restoration of platelet counts compatible with adequate hemostasis rather than achieving physiological platelet counts. The first line treatments focus on the inhibition of autoantibody production and platelet degradation, whereas second-line treatments include immunosuppressive drugs, such as Rituximab, and splenectomy. Finally, third-line treatments aim to stimulate platelet production by megakaryocytes. This review discusses the pathophysiology of ITP and how the different treatment modalities affect the pathogenic mechanisms. Keywords: immune thrombocytopenia (ITP); autoimmunity; T cells; B cells; platelets

1. Introduction Primary immune thrombocytopenia (ITP) is an acquired immune disorder characterized by an isolated thrombocytopenia (peripheral blood platelet count